Clinical Application of Four Approaches in Cervical Cancer Screening
Ruizhen LI,Na WULAN,Zhihua LIU,Qian WANG,Junhua LI,Qing LI,Ni LI,Zhihong LIU,Jufang SHI,Changhuai ZHANG,Yanqiu ZHOU,Bin LIU,keiming WENG,Ruifang WU,Youlin QIAO
DOI: https://doi.org/10.3969/j.issn.1000-8179.2009.01.001
2009-01-01
Chinese Journal of Clinical Oncology
Abstract:Objective: To evaluate the clinical application of four approaches to cervical cancer screening. Methods: A total of 1,137 women of 15 to 59 years old selected from Huaqiaocheng community, Nanshan district of Shenzhen received a population-based cervical cancer screening between November 2004 and December 2004. All of the subjects were investigated by four approaches, including visual inspection with acetic acid (VIA), colposcopy, hybrid capture II (HC-II) human papillomavirus (HPV) test and liquid-based cytology test (LCT). Subjects with abnormal or suspicious findings during colposcopy received biopsies. HPV-positive subjects with atypical squamous cells of undetermined sign (ASCUS) based on LCT or HPV-negative patients with low grade squamous intraepithelial lesion (LSIL) based on LCT had biopsies during colposcopy. The pathology results were used as gold standards to evaluate the four approaches for screening for cervical cancer. Results: A total of 122 biopsy specimens were obtained. Pathological examination found no cases of cervical cancer, 3 cases of grade III cervical intraepithelial neoplasia (CIN), 11 cases of grade II CIN, 36 cases of grade I CIN, 69 cases of chronic cervicitis and metaplasia of squamous epithelium, and 3 cases of normal cervix. The HPV-positive rate was 14.0% by HC-II, the LCT-positive rate was 12.6%, the VIA-positive rate was 12.5%, and the colposcopy positive rate was 13.6%. The HPV-positive rate and LCT positive rate increased as the pathological grade of cervical lesions increased (P<0.005). The sensitivity, specificity, accuracy, positive prevalue, negative prevalue, positive likelihood ratio and negative likelihood ratio were 100%, 87.1%, 87.3%, 8.8%, 100%, 11.3 and 23.5% for HC-II HPV for detecting high grade cervical lesions; 92.9%, 88.4%, 88.5%, 9.1%, 99.9%, 8.0 and 8.0% for LCT; 35.7%, 96.0%, 95.3%, 10.0%, 99.2%, 8.9, and 67.0% for VIA; and 50%, 86.8%, 86.4%, 4.5%, 99.3%, 3.8, and 57.6% for colposcopy. Conclusion: HC-II high risk HPV detection and LCT are presently two promising approaches for cervical cancer screening. The sensitivity of VIA and colposcopy is lower for detecting high grade cervical lesions and is therefore not suitable for screening, but their specificity and negative prevalue are higher and readily applicable for clinical testing.